Drug Type: Small Molecule
Conditions: ALS, Alzheimer’s disease, Batten’s disease
Mechanism Type: Neuroprotection
Mechanism: XN-001 is a small molecule synthetic derivative of the natural brain metabolite Lanthionine Ketimine (LK). It targets collapsin response mediator protein (CRMP2). XN-001 has shown promising results in mouse models of Alzheimer’s disease and ALS.
U.S. Status for ALS: Preclinical
 Emerging Biological Importance of Central Nervous System Lanthionines. Hensley K. Molecules. 2010;15: 5581-5594.
 Novel Alzheimer’s disease (AD) drug to be developed by Xonovo Inc. FierceBiotech Research, 15 Oct 2013. Accessed 11 Mar 2016 from http://www.fiercebiotechresearch.com/press-releases/novel-alzheimers-disease-ad-drug-be-developed-xonovo-inc.
 J&J, Takeda team up to open Israeli biotech incubator. Shamah, D. Times of Israel, 19 Jan 2015. Accessed 11 Mar 2016 from http://www.timesofisrael.com/jj-takeda-team-up-to-open-israeli-biotech-incubator.
Last updated March 11th, 2016